<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02248220</url>
  </required_header>
  <id_info>
    <org_study_id>248.360</org_study_id>
    <nct_id>NCT02248220</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease</brief_title>
  <official_title>Observation of the Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Assessment of daily maintenance dose of Sifrol®, L-dopa sparing effect, effect on tremor,
      depression, anhedonia and tolerability
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 1998</start_date>
  <primary_completion_date type="Actual">October 1999</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cumulative daily doses of Sifrol®</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>Changes in the doses between visits are evaluated using Wilcoxon's signed rank test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in cumulative daily doses of L-dopa</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>Changes in the doses between visits are evaluated using Wilcoxon's signed rank test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Short Parkinson Evaluation Scale (SPES) total score</measure>
    <time_frame>Baseline, after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in SPES subscales</measure>
    <time_frame>Baseline, after 8 weeks</time_frame>
    <description>Psychopathological disturbances, Activities of daily living, Evaluation of motor function, Tremor, Resting Tremor, Postural tremor, Complications of therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Snaith-Hamilton-Pleasure-Scale total score</measure>
    <time_frame>Baseline, after 8 weeks</time_frame>
    <description>patients with SPES depression &gt;= 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Tremor Impact Scale (TIS-D) total score</measure>
    <time_frame>Baseline, after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in global Parkinson's Disease (PD) symptoms</measure>
    <time_frame>Baseline, after 8 weeks</time_frame>
    <description>Akinesia, anhedonia, depression, dyskinesia, motor fluctuation, cognitive disturbances, rigor and tremor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of efficacy by investigator on a 5-point scale</measure>
    <time_frame>after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of tolerability by investigator on a 5-point scale</measure>
    <time_frame>after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse drug reactions</measure>
    <time_frame>up to 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">657</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Parkinson's disease patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramipexole</intervention_name>
    <arm_group_label>Parkinson's disease patients</arm_group_label>
    <other_name>Sifrol®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with advanced idiopathic Parkinson's diease recruited at specialist practices and
        hospitals
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with advanced idiopathic Parkinson's disease for whom combined treatment with
             Sifrol and L-dopa was indicated

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2014</study_first_submitted>
  <study_first_submitted_qc>September 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2014</study_first_posted>
  <last_update_submitted>September 22, 2014</last_update_submitted>
  <last_update_submitted_qc>September 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

